Advances of clinical research on alternative therapy for hemophilia A,coagulation factor Ⅷ
Hemophilia A(HA)is a rare X-chromosome linked recessive hemorrhagic disorder caused by the deficiency or dysfunction of coagulation factor Ⅷ(FⅧ)in the blood.The incidence of HA is low,the cost of treatment is high,and there is no effective radical treatment at present.On-demand alternative treatment is still the most effective way to treat HA in our country.However,HA patients need lifelong medication,the existing drugs have short half-life,high injection frequency,easy to produce coagulation FⅧ inhibitors,and poor quality of life of patients.In view of such unmet clinical needs,this paper mainly reviewed the clinical research progress of three alternative therapeutic drugs:plasma-derived human coagulation FⅧ,recombinant human coagulation FⅧ and long-acting recombinant human coagulation FⅧFc fusion protein,to provide new ideas and basis for later drug development and clinical treatment.
hemophilia Areplacement therapyplasma-derived human coagulation factor Ⅷrecombinant human coagulation factor Ⅷreombint human coagulation factor Ⅷ-Fc fusion protein
NETL
NSTL
万方数据
